Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Optimizing therapy with allopurinol: Factors limiting hypouricemic efficacy
The American Journal of the Medical Sciences, 03/20/08

Chung Y et al. - Allopurinol is a moderately active hypouricemic drug, that acts by inhibiting the xanthine oxidoreductase by oxypurinol, the active metabolite of allopurinol. Optimal use of allopurinol involves individualization of dose to attain a sufficient decrease in plasma urate concentrations. The initial use of an anti-inflammatory drug or low-dose colchicine decreases but does not eliminate the development of acute attacks of gout during the initiation of therapy with allopurinol. Monitoring of oxypurinol concentrations has shed some light on the efficacy of allopurinol but more data are required particularly in patients with renal impairment.

<< Previous
The clinical spectrum of IgM-related amyloidosis: A French...

Next >>
Identification of cytokines that might enhance the promoter...